Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIM (Advanced Immune Modulator)
- Development stage
- Unknown
- Lead developer
- AIM ImmunoTech
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
AIM (Advanced Immune Modulator) is an injectable solution marketed as an alternative treatment for various serious conditions, including cancer, HIV/AIDS, and viral hepatitis. Developed by Alpha-Omega Labs, the formulation typically contains zinc chloride, citric acid, and a blend of amino acids such as L-lysine and L-proline. It is often described by its proponents as an immune system enhancer or a botanical injectable, although its primary active ingredient, zinc chloride, is a known caustic agent. The product has not been approved by the FDA or other major regulatory bodies for any medical indication and has been the subject of significant regulatory scrutiny and legal action due to safety concerns and unproven therapeutic claims. It is typically administered via intramuscular or subcutaneous injection.
- Brand names
- AIMAIM Injectable
- Other names
- Advanced Immune ModulatorAIM-1AIM1AIM 1AIM-2AIM2AIM 2
02
Targets
TREM1 (Triggering receptor expressed on myeloid cells 1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on AIM (Advanced Immune Modulator).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM (Advanced Immune Modulator).